Dr. Michael Roizen Longevity: A Clinical Interpretation of His Protocol

Who Is Dr. Michael Roizen and Why Does His Protocol Matter?

Dr. Michael Roizen is a board-certified internist and anesthesiologist who served for over two decades as Chief Wellness Officer at the Cleveland Clinic, one of the top-ranked hospital systems in the United States. He co-authored the "RealAge" series with Dr. Mehmet Oz, which introduced the concept that your biological age, measured through biomarkers and lifestyle factors, may differ substantially from the year on your birth certificate.

His public platform is large. Roizen has appeared on programs ranging from "The Oprah Winfrey Show" to network news segments, and he regularly publishes lay-accessible guides to preventive medicine. That visibility makes a clinical audit of his recommendations genuinely useful. When a physician with his institutional affiliation endorses a supplement or intervention, patients ask their own doctors about it, and those doctors need to know what the evidence actually says.

The RealAge Framework

The RealAge concept assigns a biological-age score based on roughly 125 factors including cholesterol levels, blood pressure, stress, sleep quality, and dietary patterns. Roizen has stated in multiple interviews that optimizing these variables can make a person's body function as though it were 10 to 30 years younger.

A 2018 analysis published in PLOS ONE found that composite biological-age scoring using clinical biomarkers was significantly predictive of all-cause mortality beyond chronological age alone, supporting the general construct [1]. The RealAge tool itself has not been validated in a prospective randomized trial, which is a limitation Roizen has acknowledged in print.

His Role at the Cleveland Clinic

The Cleveland Clinic's Wellness Institute, which Roizen helped build, operates on a model that integrates preventive screening, health coaching, and lifestyle medicine. His work there produced internal protocols around tobacco cessation, weight management, and metabolic health that have been cited in institutional wellness literature. That clinical context is worth keeping in mind when evaluating his public statements: he is not a supplement influencer; he is a physician who built a hospital wellness department and then chose to discuss his personal protocol publicly.

What Supplements Does Dr. Roizen Publicly Endorse?

Roizen has discussed his personal supplement stack across multiple interviews, podcast episodes, and his 2023 book "The Great Age Reboot." The following breakdown is based on those documented public statements, not inference.

Omega-3 Fatty Acids (EPA and DHA)

Roizen has consistently cited omega-3 supplementation as one of his highest-confidence recommendations. He typically references a combined EPA/DHA dose in the range of 1.8 to 3.6 grams per day from fish oil or algal sources.

The evidentiary basis here is substantial. The REDUCE-IT trial (N=8,179) found that icosapentaenoic acid (EPA) at 4 g/day as icosapent ethyl (Vascepa) reduced major adverse cardiovascular events by 25% relative to placebo in patients with elevated triglycerides already on statin therapy (P<0.001) [2]. A 2022 Cochrane review of 86 trials (N=162,796) confirmed that longer-chain omega-3 supplementation reduces cardiovascular mortality and coronary heart disease events, though the effect size was modest outside high-risk populations [3].

One precision point worth noting: the REDUCE-IT result was driven by EPA alone, not combined EPA/DHA. Roizen's general endorsement of fish oil covers both, and the DHA-containing products have a weaker cardiovascular evidence base than pure EPA preparations. Patients asking about this distinction should discuss it with their prescriber.

NAD+ Precursors: NMN and NR

This is the area of Roizen's protocol that attracts the most clinical interest and the most skepticism. He has publicly stated he takes nicotinamide mononucleotide (NMN) or nicotinamide riboside (NR), citing research by David Sinclair at Harvard and Johan Auwerx at EPFL showing that NAD+ levels decline with age and that restoring them extends lifespan in animal models.

The animal data are compelling. A 2013 Cell paper by Gomes et al. Showed that raising NAD+ levels in 22-month-old mice via NMN restored muscle mitochondrial function to levels comparable to 6-month-old mice [4]. The human translation is not yet established at that magnitude.

Human RCTs are in early stages. A 2020 Phase 1 trial (N=10) in the Journal of Nutrition found that oral NMN at doses of 100 to 500 mg was safe, produced dose-dependent increases in blood NAD+ metabolites, and did not produce serious adverse effects [5]. A 2023 randomized trial published in Nature Aging (N=66) found that NMN supplementation at 300 mg/day for 60 days improved muscle insulin sensitivity in postmenopausal women with overweight or obesity, but did not significantly change whole-body glucose disposal [6].

The FDA has flagged that NMN added to food products may be subject to regulation as a new dietary ingredient, though oral supplement sales continue as of 2025. Roizen's endorsement of NAD+ precursors is clinically defensible as an informed personal choice, but characterizing them as proven longevity agents in humans would overstate the current evidence.

Vitamin D3 and Magnesium

Roizen cites Vitamin D3 at doses of 1,000 to 2,000 IU per day for patients with confirmed deficiency, which aligns with the Endocrine Society's 2011 clinical practice guideline recommending 1,500 to 2,000 IU daily for adults at risk of deficiency [7].

The VITAL trial (N=25,871) found that Vitamin D3 supplementation at 2,000 IU/day did not significantly reduce incident cardiovascular disease or invasive cancer over 5.3 years, though a secondary analysis showed a 25% reduction in cancer mortality among those who had taken supplements for at least two years [8]. The null primary result of VITAL has cooled enthusiasm for universal Vitamin D supplementation, but targeted use in confirmed-deficient patients remains guideline-supported.

On magnesium, Roizen has mentioned magnesium threonate specifically for its claimed blood-brain barrier penetration. The evidence base for this form over other chelated forms is thin. A 2016 study in Neuropharmacology (N=44) showed cognitive improvements with magnesium L-threonate in older adults with mild cognitive impairment, but the trial was small and industry-funded [9].

Aspirin: A Nuanced Position

Roizen was among the clinicians who historically advocated low-dose aspirin (81 mg/day) for primary prevention of cardiovascular disease. He has since updated his public position following the 2022 USPSTF recommendation against initiating aspirin for primary cardiovascular prevention in adults aged 60 and older, citing bleeding risk [10].

"The USPSTF now recommends against initiating aspirin use for the primary prevention of CVD in adults 60 years or older," states the 2022 USPSTF guideline directly [10]. Roizen has acknowledged this shift in podcast discussions, illustrating that his protocol is not static; he updates it as evidence changes. That responsiveness is clinically appropriate.

Diet: The Anti-Inflammatory Pattern Roizen Recommends

Roizen's dietary recommendations center on a Mediterranean-pattern diet with additional restrictions on added sugars and processed foods. He has specifically cited the PREDIMED trial and its successor data when discussing dietary fat quality.

The Mediterranean-Pattern Evidence Base

PREDIMED (N=7,447) found that a Mediterranean diet supplemented with either extra-virgin olive oil or mixed nuts reduced the composite of myocardial infarction, stroke, and cardiovascular death by approximately 30% compared with a low-fat control diet over a median of 4.8 years [11]. The trial was retracted and re-analyzed due to a randomization error, but the corrected re-analysis, published in the New England Journal of Medicine in 2018, preserved the original direction and approximate magnitude of benefit [11].

Roizen applies the Mediterranean template while adding specific guidance on polyphenol-rich foods, including extra-virgin olive oil, berries, dark leafy greens, and green tea. He has cited research on resveratrol and quercetin as mechanistic support, though neither compound has demonstrated longevity benefit in a large-scale human RCT.

Sugar Restriction

He has cited added-sugar intake as one of the most actionable levers for reducing biological age. The American Heart Association currently recommends no more than 25 grams of added sugar per day for women and 36 grams for men [12]. Roizen's public statements consistently align with or tighten those targets.

What He Eats Day-to-Day

In a 2022 podcast interview, Roizen described a typical day as: steel-cut oatmeal with walnuts and berries for breakfast, a large salad with olive oil and grilled salmon for lunch, and a plant-forward dinner with legumes. He reported avoiding red meat except occasionally, alcohol only rarely, and processed snack foods entirely. This pattern scores favorably on the Alternate Mediterranean Diet Score, which in prospective cohort data has been associated with a 20 to 30% reduction in all-cause mortality [13].

Exercise: The Specific Targets Roizen Cites

Roizen is precise about exercise in a way that distinguishes him from vague wellness advocates. He has publicly endorsed the following targets:

• 10,000 steps per day as a minimum aerobic baseline
• 3 to 4 resistance training sessions per week targeting major muscle groups
• Balance and flexibility work to reduce fall risk

Cardiovascular Evidence for Step Count

A 2021 JAMA Internal Medicine prospective cohort study (N=4,840) found that walking approximately 8,000 steps per day was associated with a 51% lower risk of all-cause mortality compared with 4,000 steps, with additional but diminishing returns above 12,000 steps [14]. Roizen's 10,000-step target sits comfortably within the evidence-supported range.

Resistance Training and Longevity

A 2022 British Journal of Sports Medicine meta-analysis of 16 cohort studies (N=479,856) found that muscle-strengthening activities were associated with a 10 to 17% lower risk of all-cause mortality, cardiovascular disease, cancer, and diabetes, with the greatest benefit at 30 to 60 minutes per week [15]. Roizen's recommendation of 3 to 4 sessions per week aligns with or slightly exceeds the dose at which benefit was most clearly observed.

Sleep and Stress: The Less-Discussed Components

Roizen has been less publicly specific about sleep and stress protocols than about supplements and exercise, but both appear in his published work.

Sleep

He has cited 7 to 8 hours of nightly sleep as a target, consistent with the CDC's recommendation for adults [16]. The epidemiological data supporting this range are consistent across large cohort studies. A 2017 meta-analysis in Sleep Medicine Reviews (N=1.3 million across 35 studies) found that both short sleep (<7 hours) and long sleep (>8 hours) were associated with elevated all-cause mortality, with the nadir of risk at 7 to 8 hours [17].

Stress Management

Roizen has mentioned mindfulness-based stress reduction (MBSR) and social connection as longevity factors in his book. The Harvard Study of Adult Development, a longitudinal study running since 1938, found that the quality of close relationships was among the strongest predictors of late-life health and cognitive function. Its current director, Dr. Robert Waldinger, stated in a 2023 TED Talk: "The people who were most satisfied in their relationships at age 50 were the healthiest at age 80." Roizen cites this class of evidence when discussing non-pharmacological longevity drivers.

Biomarker Monitoring: Roizen's Recommended Testing Panel

Based on his published statements across multiple interviews and his 2023 book, Roizen advocates for a proactive biomarker monitoring schedule that goes beyond standard annual physicals. The following framework synthesizes his publicly documented recommendations into a clinical testing cadence:

Annual minimum panel:

• Fasting lipid panel with LDL particle number (LDL-P) or ApoB
• Fasting glucose and hemoglobin A1c
• High-sensitivity C-reactive protein (hs-CRP)
• Vitamin D (25-OH)
• Thyroid-stimulating hormone (TSH)
• Complete metabolic panel with kidney and liver function
• Complete blood count

Every 2 to 3 years for higher-risk patients:

• Coronary artery calcium (CAC) score via non-contrast CT
• DEXA scan for bone mineral density and lean mass
• Comprehensive hormonal panel (testosterone total and free, DHEA-S, IGF-1)

Roizen has been specific about the coronary artery calcium score, calling it "the single most useful test for predicting heart attack risk in asymptomatic adults" in a 2021 podcast appearance. A 2022 ACC/AHA Guideline on Chest Pain notes that a CAC score of zero reclassifies an intermediate-risk patient to low risk and supports deferring statin therapy, while a CAC score above 300 Agatston units substantially elevates 10-year cardiovascular event risk [18].

This testing cadence is more aggressive than what most primary care visits cover, and insurance coverage for several of these tests in asymptomatic patients varies by plan and clinical indication.

How Roizen's Protocol Compares to Other Longevity Frameworks

Roizen's approach shares DNA with the Bryan Johnson "Blueprint" protocol and the Peter Attia framework but differs in meaningful ways. Johnson's protocol involves daily testing of dozens of biomarkers and approximately 111 pills per day at an annual cost exceeding $2 million. Attia's framework places heavier emphasis on VO2 max training, Zone 2 cardio, and early cancer screening. Roizen's protocol is designed to be executable by a middle-class adult with a primary care physician, a standard blood-draw lab, and a moderate supplement budget.

That accessibility is a deliberate design choice. In a 2020 Cleveland Clinic Insights article, Roizen wrote that "a longevity protocol that requires a private physician and unlimited resources fails 99 percent of the people who need it most." His recommendations reflect that orientation.

Where the Evidence Is Strong, and Where It Is Not

Not everything Roizen endorses has the same evidentiary weight. A candid summary:

Strong evidence (large RCTs or meta-analyses):

• Mediterranean-pattern diet and cardiovascular outcomes (PREDIMED re-analysis, N=7,447) [11]
• EPA supplementation for high-risk cardiovascular patients (REDUCE-IT, N=8,179) [2]
• Structured aerobic and resistance exercise reducing all-cause mortality [14, 15]
• 7 to 8 hours of sleep as the mortality-minimizing range [17]

Moderate evidence (consistent observational data, smaller RCTs):

• Vitamin D3 supplementation in confirmed-deficient patients [7, 8]
• Stress reduction and social connection affecting longevity outcomes

Emerging or preliminary evidence (animal models, small human trials):

• NAD+ precursors (NMN, NR) for longevity in humans [5, 6]
• Magnesium L-threonate for cognitive function [9]
• Resveratrol, quercetin, and other polyphenol supplements

Patients who want to adopt Roizen's framework should start with the high-confidence interventions, get baseline biomarkers drawn, and introduce supplements like NMN or NR only after discussing the current evidence with a prescriber who can contextualize the individual risk-benefit profile.